Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/29840
Title: | The changing landscape of data monitoring committees-Perspectives from regulators, members, and sponsors | Authors: | Bhattacharyya, Amit Gallo, Paul Crisp, Adam LaVange, Lisa MOLENBERGHS, Geert Petavy, Frank Seltzer, Jonathan |
Issue Date: | 2019 | Publisher: | WILEY | Source: | BIOMETRICAL JOURNAL, 61(5), p. 1232-1241 | Abstract: | Data Monitoring Committees (DMCs) are an integral part of clinical drug development. Their use has evolved along with changing study designs and regulatory expectations, which has associated statistical and ethical implications. Although there is guidance from the different regulatory agencies, there are opportunities to bring more consistency to address practical issues of establishing and operating a DMC. Challenging issues include defining the scope of DMC decisions, the regulatory requirements and expectations, the perceived independence of DMCs, the specific focus primarily on safety, etc. Wider use of adaptive clinical trial designs in recent years introduce additional challenges in terms of trial governance and the complexity of DMC activities. A panel comprised of clinical and statistical experts from across academia, industry, and regulatory agencies shared their experience and thoughts on the importance of these aspects and offered perspectives on the future of the DMCs. This paper documents the thinking from the panel session at the CEN-ISBS conference held in Vienna, Austria, 2017. | Notes: | [Bhattacharyya, Amit; Seltzer, Jonathan] ACI Clin, 3 Bala Plaza West,Suite 402,251 St Asaphs Rd, Bala Cynwyd, PA 19004 USA. [Gallo, Paul] Novartis, One Hlth Plaza, E Hanover, NJ USA. [Crisp, Adam] GSK, Uxbridge, Middx, England. [LaVange, Lisa] Univ N Carolina, Dept Biostat, CB 8030, Chapel Hill, NC USA. [Molenberghs, Geert] Univ Hasselt, CenStat, Hasselt, Belgium. [Petavy, Frank] European Med Agcy, London, England. | Keywords: | adaptive design; clinical trial; data monitoring committee (DMC); EMA; futility; regulatory guideline; USFDA;adaptive design; clinical trial; data monitoring committee (DMC); EMA; futility; regulatory guideline; US FDA | Document URI: | http://hdl.handle.net/1942/29840 | ISSN: | 0323-3847 | e-ISSN: | 1521-4036 | DOI: | 10.1002/bimj.201700307 | ISI #: | 000483693900011 | Rights: | 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim | Category: | A1 | Type: | Journal Contribution | Validations: | ecoom 2020 |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Bhattacharyya_et_al-2019-Biometrical_Journal.pdf Restricted Access | Published version | 181.21 kB | Adobe PDF | View/Open Request a copy |
Biometrical Journal Resubmit - Nov 19 2018_clean.pdf Restricted Access | Peer-reviewed author version | 128.14 kB | Adobe PDF | View/Open Request a copy |
WEB OF SCIENCETM
Citations
5
checked on Oct 13, 2024
Page view(s)
132
checked on Sep 6, 2022
Download(s)
132
checked on Sep 6, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.